KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Cash & Equivalents (2016 - 2025)

Cme (CME) has disclosed Cash & Equivalents for 17 consecutive years, with $2.4 billion as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 37543.08% to $2.4 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 billion, a 37543.08% increase, with the full-year FY2024 number at $2.9 billion, down 0.67% from a year prior.
  • Cash & Equivalents was $2.4 billion for Q3 2025 at Cme, up from $1.4 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $2.9 billion in Q4 2023 to a low of $4.5 million in Q1 2021.
  • A 5-year average of $1.2 billion and a median of $1.4 billion in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 56568.75% in 2022, then plummeted 99.75% in 2023.
  • Cme's Cash & Equivalents stood at $4.8 million in 2021, then surged by 56568.75% to $2.7 billion in 2022, then increased by 7.05% to $2.9 billion in 2023, then decreased by 0.67% to $2.9 billion in 2024, then dropped by 15.41% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for CME's Cash & Equivalents are $2.4 billion (Q3 2025), $1.4 billion (Q1 2025), and $2.9 billion (Q4 2024).